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background:  Renal insufficiency (RI) is a well known limiting factor in the evaluation of myocardial infarction (MI) with troponin (Tn); this is 
particularly true for TnT. However it is unknown in which amount the stage of RI influences Tn level. To this aim, we investigated the area under the 
curve (AUC) of 3 different Tn assays (2 TnT and 1 TnI) according to the stage of RI.
methods: 452 pts with chest pain were enrolled in the ER, 392 (86%) were discharged without diagnosis of Acute Coronary Syndrome (ACS) and 
60 (14%) with a diagnosis of ACS. We evaluated 3 different assays: cTnI LOCI (Siemens), Roche cTnT and Roche hsTnT. The population was classified 
according to the glomerular filtration rate (GFR) level: GFR≥ 60 ml/min (stage I-II), GFR<60>30 ml/min (stage III), GFR <30 ml/min (stage IV-V). The 
AUC was assessed either by continuous values (Cont) and categorical values (Cat).
results: each Tn lost predictive value for MI with increasing stage of RI, in particular hsTnT in stage IV-V had an AUC of 0.500 (see table).
AUC Cont. AUC Cat. SE SP
All groups
cTnI LOCI(Siemens) 0.819 0.795 63% 96%
Roche cTnT 0.804 0.784 62% 95%
Roche hsTnT 0.865 0.780 77% 80%
GFR≥ 60 ml/min (stage I-II)
cTnI LOCI(Siemens) 0.808 0.806 64% 97%
Roche cTnT 0.772 0.770 56% 98%
Roche hsTnT 0.888 0.809 72% 90%
GFR<60>30 ml/min (stage III)
cTnI LOCI(Siemens) 0.835 0.806 68% 93%
Roche cTnT 0.824 0.788 64% 93%
Roche hsTnT 0.808 0.693 75% 64%
GFR <30 ml/min (stage IV-V)
cTnI LOCI(Siemens) 0.740 0.669 43% 91%
Roche cTnT 0.623 0.584 71% 46%
Roche hsTnT 0.623 0.500 - -
Conclusion: our study demonstrates that Tn levels have a poor performance in case of advanced RI, in particular hsTnT use should be avoided 
because of its null discrimination power.
